A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively.
Teladoc Health Announces Executive Leadership Change
Laizer Kornwasser, President of Enterprise Growth and Global Markets What You Should Know: – Teladoc Health, Inc. has announced a significant change in its executive
July 8, 2024